RxDoctor Payments Data

Nedal Adi, MD

Family Medicine · Webster, TXNPI 1093102477

Payments from drug & device makers

$71,975in general payments, 2019–2025

Across 340 payments — averaging $211.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$60K
  • Ionis Pharmaceuticals, Inc.$5K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$1K
  • AbbVie$798
  • Amgen$788
  • Novo Nordisk$594
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$5,79399%
  • Education$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,975 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$128,887
Medicare patients
373
Services billed
2,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$124,166
EliquisApixaban144$90,532
JanuviaSitagliptin Phosphate48$55,526
FarxigaDapagliflozin Propanediol76$53,154
LinzessLinaclotide51$44,329
JardianceEmpagliflozin46$38,717
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$26,053
TrulicityDulaglutide23$25,839
TradjentaLinagliptin49$20,380
MyrbetriqMirabegron35$19,341
Bydureon BciseExenatide Microspheres18$16,653
Breo ElliptaFluticasone/Vilanterol24$12,333
Janumet XrSitagliptin Phos/Metformin Hcl11$11,163
Sevelamer Carbonate20$9,902
Atorvastatin Calcium612$6,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$594$126,911105 claims
PfizerEliquis$217$90,532144 claims
MerckJanuvia, Janumet Xr$158$66,68959 claims
Boehringer IngelheimJardiance, Tradjenta$92$59,09795 claims
AstraZenecaFarxiga$284$53,15476 claims
AbbVieLinzess, Synthroid$798$46,34569 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$408$43,70681 claims
Lilly USA, LLCTrulicity$260$25,83923 claims
Astellas Pharma US IncMyrbetriq$96$19,34135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →